Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Pfizer is presented as the preferred long-term 2026 investment, supported by its $10 billion Metsera acquisition and expansion into obesity care and oncology, although FY2025 revenue declined 1.6% to $62.6 billion. Bristol Myers Squibb generated higher free cash flow of $12.8 billion versus Pfizer's $9.1 billion and raised its full-year revenue outlook, but faces patent-expiry, pricing, litigation, and leverage risks. Both trade at low valuation multiples, with Pfizer at 9.3x forward P/E and 2.5x sales versus BMS at 9.1x and 2.7x, respectively.

Analysis

The valuation gap between BMY and PFE is too narrow to justify treating them as equivalent patent-cliff trades. BMY’s nearer-term earnings resilience is likely to be monetized through 2026 as newer-brand growth offsets legacy erosion, but the market will increasingly capitalize post-2028 cash flow at a lower multiple because Eliquis concentration, IRA exposure, and a more levered balance sheet constrain capital-allocation flexibility. PFE’s downside is more execution-dependent, yet its oncology platform can create commercial synergies across diagnostics, field force, and combination regimens that a stand-alone obesity asset cannot; successful pipeline readouts could drive a multiple rerating before meaningful revenue arrives.

The non-obvious obesity implication is that PFE is not simply a third entrant behind LLY and NVO. A differentiated oral, tolerability, or maintenance-profile candidate would expand payer access and the treated population rather than require share theft from injectable incumbents. Conversely, absent clinically meaningful differentiation, obesity investment becomes an expensive R&D and acquisition-cost overhang: PFE would face rebate-heavy formularies, lower net pricing, and weak returns on capital. The next 1-3 months are primarily catalyst-light and favor BMY’s earnings visibility; the 6-18 month relative return will be dictated by PFE trial data and evidence that Seagen-derived launches are converting into durable growth.

Consensus appears overly comfortable with PFE’s dividend as a floor and overly focused on headline pipeline optionality. The key risk is not only trial failure but a middling result that forces management to compete on price, delaying deleveraging and keeping the stock in a value trap. For BMY, the contrary risk is that a single guidance raise does not resolve the terminal-value problem; sustained growth in its new-product portfolio must exceed the pace of legacy-product decline to prevent another de-rating.

Key Decisions for Investors

• Initiate a 6-12 month long BMY / short PFE pair at equal dollar exposure for near-term earnings execution; target 10-15% relative return. Exit if BMY’s new-product growth decelerates below legacy-revenue erosion for two consecutive quarters, or if PFE delivers clearly differentiated obesity efficacy/tolerability data.
• Maintain PFE as a 12-24 month event-driven long only after confirming the clinical profile, enrollment completion, and expected readout dates of the obesity program; use a 7-10% position risk budget rather than underwriting obesity revenue today. A credible differentiated readout could support 20%+ upside through multiple expansion, while an undifferentiated result leaves downside toward traditional ex-growth pharma valuation.
• Avoid chasing LLY and NVO solely on PFE’s obesity optionality. Instead, monitor payer commentary and net-price trends: broad formulary access for a differentiated PFE candidate would be incrementally negative for LLY/NVO margins, whereas delayed or noncompetitive data reinforces their pricing power.
• Watch CYTK as a litigation and competitive-intelligence signal rather than a direct hedge: material legal or commercial friction involving BMY could pressure BMY’s oncology/neuroscience strategic flexibility, but the article provides insufficient case-status or damages data to support a directional CYTK trade.